Targeted Therapies in the Management of Non-Small Cell Lung Cancer. A Multi-Disciplinary Approach
|
|
- Christine Byrd
- 5 years ago
- Views:
Transcription
1
2 Targeted Therapies in the Management of Non-Small Cell Lung Cancer A Multi-Disciplinary Approach
3 Course Faculty Medical Oncologists: Dr. Barb Melosky British Columbia Cancer Agency, Vancouver, BC Dr. Jeff Rothenstein Lakeridge Health Oshawa, Oshawa, ON Dr. Sunil Verma Odette Cancer Center, Toronto, ON Radiation Oncologist: Dr. Patrick Cheung Odette Cancer Center, Toronto, ON Pathologists: Dr. Ming Tsao Princess Margaret Hospital, Toronto, ON
4 Disclosures Dr. Barb Melosky o Advisory Board Astra Zeneca, Roche, Boehringer Ingelheim, Pfizer, Lilly Dr. Jeff Rothenstein o Advisory Board Lilly, BMS; Grants/honorarium Novartis; Clinical trials Roche, BMS, AstraZeneca, Boehringer Ingelheim, Novartis Dr. Sunil Verma o Advisory Board AstraZeneca, Roche, Boehringer Ingelheim, Novartis, Lilly Dr. Patrick Cheung o None to declare Dr. Ming Tsao o Grants/honorarium Pfizer, Merck, Roche, AstraZeneca, Boehringer Ingelheim
5 Course Objectives 1. To review the evidence for use of biomarkers to help make treatment decisions for patients with advanced non small cell lung cancer 2. To discuss the current opportunities and challenges in integrating biomarkers in clinical care of lung cancer patients 3. To review the latest evidence on targeted therapies incorporating biomarkers 4. To discuss the emerging roles of radiotherapy in the management of metastatic NSCLC.
6 Course Outline Module 1: Case Study & NSCLC Treatment Overview Module 2: Molecular Testing in NSCLC Module 3: EGFR/TKI: Evidence Module 4: ALK Inhibitors: Evidence
7 Targeted Therapies in the Management of Non-Small Cell Lung Cancer: A Multi- Disciplinary Approach Module 1: Case Study & NSCLC Treatment Overview Dr. Patrick Cheung Radiation Oncologist, Odette Cancer Center, Toronto, ON
8 Module 1 Objectives Discuss a case study to illustrate best practices for patient diagnosis and treatment options in NSCLC. Describe appropriate treatment options for NSCLC patients based on their particular patient/tumour profiles. Review the clinical data for treatment options and management of NSCLC in patients.
9 Case Study 56 year old Caucasian male presents with two month history of shortness of breath and low back pain Previous medical history o Hypertension x 10 years - on Ramipril o Type II Diabetes x 8 years on Metformin o No previous Coronary disease/renal disease o Smoking History: 10 pack years
10 Case Study History of presenting illness o Cough and shortness of breath x 2 months o Dypnea with one flight of stairs o CXR confirms a suspicious R lower lung mass o Back pain x 2 months o Limiting activity increased with any activity o No neurological symptoms
11 Chest CT Scan
12 Other Related History Overall ECOG Performance Status of 1 Staging investigations: o CT Chest R lower lung mass and hilar adenopathy o CT Abdomen No evidence of Liver involvement o Bone Scan: Bone metastases T9, Left iliac bone, R ischium o MRI head multiple small volume (<1cm) brain metastases throughout brain with no significant edema o PET Scan evidence of FDG avid lung mass, hilar adenopathy and bone lesions
13 CT Scan Evidence of Bone Mets
14 MRI Brain Mets
15 MRI Brain Mets
16 Tissue is the Issue Pre-Test Question What is your investigation of choice for this patient to obtain tissue? 1. Bronchoscopy and Biopsy 2. Mediastinoscopy 3. Endobronchial Ultrasound 4. CT Guided Lung Biopsy 5. Bone biopsy
17 Case Study - Biopsy Results Core Biopsy of Right Lower Lung is performed: o Moderately differentiated adenocarcinoma
18 Biomarkers Who initiates the biomarker tests at your institution? 1. Surgeon 2. Respirologist 3. Interventional Radiologist 4. Pathologist 5. Radiation Oncologist 6. Medical Oncologist
19 Patient/Tumor Profile For which patients do you request biomarkers for? 1. All Advanced Non-Small Cell Lung Cancer 2. Non-Squamous Advanced Non-Small Cell Lung Cancer 3. Non-Smokers 4. Asian 5. Adenocarcinoma 6. Females 7. Combination of one of the above
20 Which Biomarker? When requesting biomarker profile test, what test do you usually request for in the first line setting? 1. EGFR 2. ALK 3. PDL-1 4. K-Ras 5. EGFR and ALK 6. All of the above
21 Molecular Profile How long does it take for you to get these results? 1. < 2 weeks weeks weeks 4. > 4 weeks
22 Case Study Treatment Decision The patient receives palliative radiation( 2000 cgy over five fractions, to T9) with good relief. How would you manage this patient now? 1. Initiate systemic chemotherapy 2. Wait to get biomarker test results prior to initiating therapy 3. Initiate radiotherapy for brain metastases
23 Treatment of NSCLC Brain Metastases in the EGFR +ve Patient No high level evidence comparing the efficacy of targeted agent alone vs upfront brain radiotherapy in molecularly selected EGFR +ve patients. Prospective phase 2 trials in EGFR +ve patients with brain metastases show >80% chance of response in the brain and up to 15 months of median intracranial PFS with erlotinib alone. In a molecularly non-selected patient population, a phase 3 trial comparing SRS + WBRT alone versus SRS + WBRT + erlotinib for patients with 1-3 brain metastases revealed significantly decreased OS and higher grade 3-5 toxicities when erlotinib was added. Only one retrospective study comparing outcomes of EGFR +ve NSCLC patients with brain metastases treated with up front erlotinib versus radiotherapy.
24 SUMMARY: o Patients treated with upfront WBRT had significantly longer intracranial PFS than those treated with erlotinib alone (median, 24 vs 16 mos, p=0.04), with no difference in OS o Patients treated with WBRT also had lower rate of failure in the brain compared to SRS
25 Treatment of NSCLC Brain Metastases in the ALK +ve Patient No high level evidence comparing the efficacy of targeted agent alone vs upfront brain radiotherapy in molecularly selected ALK +ve patients. Prospective trials in ALK +ve patients with brain metastases treated with crizotinib show >50% chance of intracranial control at 12 weeks and up to 7 months of median freedom from intracranial progression. One retrospective multi-institutional study revealing a high rate of intracranial progression in patients treated with targeted agents in ALK+ve NSCLC patients with brain metastases often requiring multiple lines of brain radiotherapy.
26 SUMMARY: o Brain metastases patients treated with upfront crizotinib have an intracranial disease control rate of 56% at 12 weeks and a median time to intracranial progression of 7 months o Brain metastases patients previously treated with brain radiotherapy and then with crizotinib have an intracranial disease control rate of 62% at 12 weeks and a median time to intracranial progression of 13.2 months
27 SUMMARY: o Patients presenting with brain metastases treated with targeted agent and brain radiotherapy have a median overall survival of 54.8 months and a median time to intracranial progression of 11.9 months o No survival difference between those who received SRS and WBRT o Strongly recommend choosing SRS over WBRT given the significant number of repeat brain treatments for these patients
28 Treatment of NSCLC Brain Metastases in the EGFR/ALK +ve Patient: Key Points Multi-disciplinary assessment should be performed in ALL patients with brain metastases, including assessment by Radiation Oncology, regardless of molecular mutation status. There is no doubt that targeted agents alone have efficacy against brain metastases with good response rates. Which patients are considered for treatment with systemic targeted agents alone without upfront brain XRT? o Small, non-bulky disease in non-eloquent areas of the brain o No significant vasogenic edema o Asymptomatic patient o Patient has to be compliant with regular follow-up imaging of the brain with MRI every 2-3 months so that early salvage with radiotherapy can be considered at time of progression.
29 Treatment of NSCLC Brain Metastases in the EGFR/ALK +ve Patient: Key Points Given no survival benefit and increased neurocognitive toxicities associated with WBRT, there is increasing interest to use SRS/SRT as treatment of brain metastases.
30
Tumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationTraditional Approaches to Treating NSCLC, Part 2: Neoadjuvant Combined Modality, Locally Advanced, and Metastatic NSCLC
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationCase Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationPalliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased
Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationA Clinical Context Report
Non-small Cell Lung Cancer in Practice An Expert Commentary With Karen Reckamp, MD A Clinical Context Report Clinical Context: NSCLC in Practice Expert Commentary Jointly Sponsored by: and Clinical Context:
More informationRadiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem
Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationApproach to biomarker testing: perspectives from various specialties
ORIGINAL ARTICLE Approach to biomarker testing: perspectives from various specialties M.R. Sung bsc,* P.M. Ellis md, S. Verma md, E. Duncan, and N.B. Leighl md mmsc* ABSTRACT Background Despite its importance
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationSteering Committee. Waiting on photo. Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD.
Steering Committee Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD MD, PhD Waiting on photo Paul Van Schil, MD, PhD William D. Travis, MD Ming-Sound Tsao,
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationLung Cancer: Diagnosis, Staging and Treatment
PATIENT EDUCATION patienteducation.osumc.edu Lung Cancer: Diagnosis, Staging and Treatment Cancer starts in your cells. Cells are the building blocks of your tissues. Tissues make up the organs of your
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationGROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:
GROUP 1: Including: Excluding: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases Solid pulmonary nodules 8mm diameter / 300mm3 volume and BROCK risk of malignancy
More informationA Case of Metastatic Lung Adenocarcinoma EGFR ve, ALK +
ESMO Preceptorship Programme Dr Najihah Abu Bakar University Malaya Medical Centre, Kuala Lumpur, Malaysia A Case of Metastatic Lung Adenocarcinoma EGFR ve, ALK + HISTORY Mr TT/ 65yo/ Male/ Non smoker/no
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationLUNG CANCER SCREENING: LUNG CANCER SCREENING: THE TIME HAS COME LUNG CANCER: A NATIONAL EPIDEMIC
: THE TIME HAS COME Physician Leader, Lung Cancer Multi-Disciplinary Program Fletcher Allen Health Care Annual Meeting Montpelier, VT - April 25, 2014 Gerald S. Davis, MD Professor of Medicine University
More informationMetastatic Bone Adenocarcinoma with Positive TTF-1 Tumor Stain with a Lung Mass: the Role and Treatment Consideration of RT
Metastatic Bone Adenocarcinoma with Positive TTF-1 Tumor Stain with a Lung Mass: the Role and Treatment Consideration of RT Case Number: RT2009-74(M) Potential Audiences: Intent Doctor, Oncology Special
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationImpact of Targeted/Immunotherapy on Gamma Knife Radiosurgery
Impact of Targeted/Immunotherapy on Gamma Knife Radiosurgery Veronica Chiang, MD Yale University Department of Neurosurgery IGKRF Scientific Session University of Pennsylvania, Philadelphia June 23-24,
More informationTHE USE OF BIOMARKERS IN TREATMENT PATTERNS
European Network of Cancer Registries Scientific Meeting 2018 THE USE OF BIOMARKERS IN TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER RODRIGO MURTEIRA National
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationSpecial Situation: Brain metastases
ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationAFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
More informationWhat to know and what to make of it
Lung Cancer Screening: What to know and what to make of it J. Matthew Reinersman, MD Assistant Professor of Surgery Division of Thoracic and Cardiovascular Surgery Department of Surgery University of Oklahoma
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Small cell lung cancer (SCLC) affects 15% of all lung cancer patients. SCLC is the most aggressive type of lung cancer. It may be treated with chemotherapy and radiation. SCLC has
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationLung Cancer Update. Disclosures. None
Lung Cancer Update Ronald J Servi DO FCCP Adjunct Assistant Professor Department of Pulmonary Medicine University of Texas MD Anderson Cancer Center Banner MD Anderson Cancer Center Gilbert, Arizona Disclosures
More informationLCA Lung Clinical Forum. 21 st October 2014
LCA Lung Clinical Forum 21 st October 2014 Welcome Dr Liz Sawicka Chair - LCA Lung Pathway Group Succession planning Dr Kate Haire Consultant in Public Health Medicine, LCA Commissioning Intentions for
More informationLUNG CANCER: LDCT DISCLOSURES NONE. Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, /9/2018
LUNG CANCER: LDCT Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, 2018 DISCLOSURES 2 NONE 1 OBJECTIVES 3 Rationale and evidence for LDCT for lung cancer screening Review
More informationCombined treatment of Brain metastases: Radiosurgery and Targeted therapy
Combined treatment of Brain metastases: Radiosurgery and Targeted therapy Stephanie Kroeze, MD PhD OVERVIEW Introduction brain metastases Targeted therapy as monotherapy Efficacy of SRS combined with Targeted
More informationOutline. The Lung Cancer Patient in 2011 Not the Marlboro Man. Lung Cancer
Outline The Lung Cancer Patient in 2011 Not the Marlboro Man Jeanne Griffin Vaughn, APN-BC, AOCN Epidemiology Staging and Patterns of Spread Clinical Presentation Treatments March 26, 2011 Lung Cancer
More informationMalignant Peripheral Nerve Sheath Tumor post Wide Excision with Multiple Lung Metastases: the Role and Treatment Consideration of RT
Malignant Peripheral Nerve Sheath Tumor post Wide Excision with Multiple Lung Metastases: the Role and Treatment Consideration of RT Case Number: RT2009-64(M) Potential Audiences: Intent Doctor, Oncology
More informationLUNG CANCER IN FOCUS. ALK Inhibitors in Non Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?
LUNG CANCER IN FOCUS Current Developments in the Management of Section Editor: Mark A. Socinski, MD ALK Inhibitors in Non Small Cell : How Many Are Needed and How Should They Be Sequenced? Alice T. Shaw,
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationUpdate on management of metastatic brain disease. Peter Hoskin Mount Vernon Cancer Centre Northwood UK
Update on management of metastatic brain disease Peter Hoskin Mount Vernon Cancer Centre Northwood UK Incidence 15-30% of patients with solid tumours will develop brain metastases Most common primary sites
More informationLung Cancer: Overview and Updates
Lung Cancer: Overview and Updates Peter H. Johnson, M.D. Medical Oncologist & Hematologist, Columbia St. Mary s Hospital February 1, 2018 Disclosures No financial interests to disclose No conflicts of
More informationLung Cancer in Older Adults.. 2 Cases
Lung Cancer in Older Adults.. 2 Cases Cancer in the Older Person Individualised management + Dr Christopher Steer Border Medical Oncology Albury-Wodonga Inaugural Chair Geriatric Oncology Interest Group
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationMaria João Cardoso, MD, PhD
Locally Advanced Breast Cancer Specific Issues in LocorregionalTreatment Surgery, MD, PhD Head Breast Surgeon Breast Unit, Champalimaud Foundation Lisbon, Portugal 1 Conflict of Interest Disclosure No
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationLara Kujtan, MD; Abdulraheem Qasem, MD
The Treatment of Lung Cancer Between 2013-2014 at Truman Medical Center: A Retrospective Review in Fulfillment of the Requirements of Standard 4.6 (Monitoring Compliance with Evidence- Based Guidelines)
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationIAN CROCKER = TIM HOWARD
Winship Cancer Institute of Emory University Radiation as Consolidation in the Treatment of Newly Diagnosed CNS Lymphoma versus After Failure of Chemotherapy Pro: Upfront Radiation Ian Crocker MD, FACR,
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationHow do weimplementimmunotherapyin routine practice? Lessons from the lung cancer experience
How do weimplementimmunotherapyin routine practice? Lessons from the lung cancer experience Pr Alexis Cortot, M.D., Ph.D. Thoracic Oncology Department, CHRU Lille Institut of Biology, Lille TAO Paris,
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationJ. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer J. C.-H. Yang 1, L.V. Sequist
More informationLung Cancer Case Study
Lung Cancer Case Study Presented by s GP Education Programme 2 Part One Initial presentation 60 year old lady, presents with a 6 week history of right sided chest pain. The pain is like a dull ache, but
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationThis online (electronic) survey contains twenty four simple questions. Those marked with an asterisk (*) must be answered.
1. Type of survey This is a retrospective survey that will NOT require the disclosure of any individual patient records or data only information about overall EGFR mutation testing practices and the outcomes
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationLong term survival in EGFR positive NSCLC patient. Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV
Long term survival in EGFR positive NSCLC patient Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV Medical history and diagnosis Male, caucasian 60 years old Former smoker (stop > 15 years)
More informationBreast Cancer with Brain Metastases: the Role and Treatment Consideration of Radiotherapy
Breast Cancer with Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-127(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose:
More informationBrain metastases: future developments. Emilie Le Rhun Lille, France
Brain metastases: future developments Emilie Le Rhun Lille, France Disclosures ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationNational Optimal Lung Cancer Pathway
National Optimal Lung Cancer Pathway This document was produced by the Lung Clinical Expert Group 2017 Document Title: National Optimal Lung Cancer Pathway and Implementation Guide Date of issue: August
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationLearning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening
Disclosure I, Taylor Rowlett, DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationUNDERSTANDING SERIES LUNG CANCER BIOPSIES LungCancerAlliance.org
UNDERSTANDING SERIES LUNG CANCER BIOPSIES 1-800-298-2436 LungCancerAlliance.org CONTENTS What is a Biopsy?...2 Non-Surgical Biopsies...3 Surgical Biopsies...5 Biopsy Risks...6 Biopsy Results...6 Questions
More informationperc noted that it was challenging to interpret the data and that limited conclusions could be drawn from these non-comparative trials. The Committee discussed the likelihood of conducting a higher-quality
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationYes, the PET-CT report dated April 13 th 2016 was included in the structured summary reviewed by a medical oncologist at Tata Memorial Centre.
May 9 th 2016 Dear Mr. Ramesh Srivastava, Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya is pleased to offer this online consultation
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationTreatment of Multiple Lung Tumors
VUmc SABR Symposium 2017 Treatment of Multiple Lung Tumors Indications and Dosimetric Considerations Dr. David Palma, MD, MSc, PhD Radiation Oncologist, London Health Sciences Centre Clinician-Scientist,
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationResearch Article The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
Chemotherapy Research and Practice, Article ID 856156, 4 pages http://dx.doi.org/10.1155/2014/856156 Research Article The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients Vanita
More informationEducational Objectives. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach.
Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach Robert A. Meguid, MD, MPH, FACS Assistant Professor of Cardiothoracic Surgery Surgical Director, Surgical
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More information